Skip to main content
. Author manuscript; available in PMC: 2017 May 4.
Published in final edited form as: Am J Transplant. 2015 Jul 30;15(12):3081–3094. doi: 10.1111/ajt.13399

Figure 3. Donor-specific CD8+ T cells exhibit an altered susceptibility profile to CoB/VLA-4 therapy after pathogen stimulation.

Figure 3

(A) Schematic of the mOVA transplant mouse system used. 104 OT-I CD8+ T cells were adoptively transferred into naïve C57BL/6 mice that were infected 48 hours later with OVA-expressing LM, gHV, or PyV. 30 days after infection, mice were transplanted mOVA skin grafts and treated with CoB (CTLA4-Ig + anti-CD154), anti-VLA-4, or CoB + anti-VLA-4. (B-D) Kaplan-Meier curves of mOVA skin allograft survival following infection with LM (B), gHV (C), or PyV (D). CoB + anti-VLA-4 therapy significantly prolonged skin allograft survival in LM-infected mice (MST 100 days, p < 0.001)(B) and gHV-infected mice (MST 20.5 days, p < 0.001)(C), but not in PyV-infected mice (MST 14 days, p = 0.232)(D). N = 4–24 animals per group.